HDL-Inflammatory Biomarker Interaction Risk Parameter
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing cardiovascular disease (CVD) risk rely heavily on cholesterol content measurements, which are inadequate in differentiating risk and guiding therapy, particularly for HDL, as they do not account for the complex multifactorial mechanisms of HDL functionality and inflammation.
Innovation Solution
A method involving the measurement of HDL particle subclasses and inflammatory biomarkers, specifically using NMR signals to determine concentrations of HDL particle subclasses and inflammatory biomarkers like GlycA, to calculate a risk parameter (HxI)CVD, which combines HDL particle concentrations with inflammatory markers to provide a more accurate CVD risk assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cholesterol content measurements (LDL-C, HDL-C) are used to assess CVD risk, then the assessment method is simple and widely applicable, but the ability to differentiate risk and guide therapy is inadequate
Solution Approach 1:
The patent segments HDL particles into multiple subclasses (HDL2a, HDL2b, HDL3a, HDL3b) based on their density and composition characteristics. This segmentation allows for more precise risk differentiation by evaluating the functional properties of each subclass rather than treating all HDL as a single entity, thereby resolving the contradiction between measurement precision and method complexity.
Solution Approach 2:
The patent employs a composite assessment approach that combines multiple parameters including HDL subclass concentrations, cholesterol content, and inflammatory biomarkers (such as CRP, IL-6, TNF-alpha) to create a comprehensive CVD risk evaluation model. This composite methodology enhances risk differentiation capability while maintaining clinical applicability through integrated analysis.
2Measurement precision
If HDL particle number (HDL-P) measurements are included in addition to cholesterol measurements, then the risk assessment becomes more comprehensive, but the complexity of the testing panel increases
Solution Approach 1:
The patent develops a multi-functional assessment platform that simultaneously measures HDL particle number, HDL cholesterol content, HDL subclass distribution, and inflammatory biomarkers using a single integrated testing system. This universal approach allows comprehensive HDL functionality assessment without proportionally increasing testing complexity, as multiple parameters are evaluated in concert rather than through separate sequential tests.
3Reliability
If inflammatory biomarkers are integrated into CVD risk assessment, then the prediction accuracy of CVD risk is improved, but the interpretation of risk factors becomes more complex
Solution Approach 1:
The patent merges multiple risk assessment dimensions (HDL subclass profiles, cholesterol measurements, and inflammatory biomarker levels) into a unified CVD risk score. This integration combines the predictive power of inflammatory markers with traditional lipid parameters, creating a single comprehensive metric that improves prediction accuracy while simplifying clinical interpretation compared to evaluating multiple separate factors.
Data Source
AI summary
Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.